Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225647712> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4225647712 endingPage "e28" @default.
- W4225647712 startingPage "e28" @default.
- W4225647712 abstract "Lead Author's Financial Disclosures Nothing to disclose. Study Funding None. Background/Synopsis Consumption of the omega-3 fatty acids (O3FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has been associated with a lower risk of cardiovascular disease (CVD). However, randomized clinical trials have failed to show consistent benefit with O3FAs in patients receiving contemporary medical care. Recent trials suggest that the formulation may have an important influence on clinical outcomes. Objective/Purpose We conducted a meta-analysis of 19 trials using both mixed O3FA products as well as prescription icosapent ethyl (IPE), which is the ethyl ester of EPA. Methods The current meta-analysis includes 15 randomized controlled trials with endpoints including non-fatal myocardial infarction (MI), coronary heart disease (CHD) death, total CHD, CVD death, total CVD, total stroke and major vascular events. The pooled rate ratios (RRs) were calculated using a fixed method. This meta-analysis also includes 4 clinical trials that assess the effect of O3FAs on coronary plaque volume and stability. All trials involved formulations with EPA alone (IPE) or in combination with DHA. Results Out of 19 trials using omega-3 fatty acids in patients with CVD risk, 5 of them employed IPE, all of which (100%) met the defined endpoints in statin treated patients. The remaining 14 trials used a combination of EPA and DHA. While only 4 (28%) met the defined endpoint, these trials with mixed O3FAs did not require statin use. Conclusions A meta-analysis of 19 CVD trials indicate that only IPE treatment was associated with reduced clinical events in statin-treated patients compared to mixed O3FAs. The basis for the distinct benefits of IPE are not fully understood but appear to be related to broad pleiotropic actions that correlate with on-treatment EPA levels. Elucidating such mechanisms for EPA will provide further insights into our understanding of CVD intervention. Nothing to disclose." @default.
- W4225647712 created "2022-05-05" @default.
- W4225647712 creator A5011063805 @default.
- W4225647712 creator A5012326453 @default.
- W4225647712 creator A5045094923 @default.
- W4225647712 creator A5078968852 @default.
- W4225647712 creator A5091574164 @default.
- W4225647712 date "2022-01-01" @default.
- W4225647712 modified "2023-09-25" @default.
- W4225647712 title "Meta-Analysis of 19 Clinical Trials using Omega-3 Fatty Acids Indicate Distinct Outcomes for Icosapent Ethyl" @default.
- W4225647712 doi "https://doi.org/10.1016/j.jacl.2021.09.039" @default.
- W4225647712 hasPublicationYear "2022" @default.
- W4225647712 type Work @default.
- W4225647712 citedByCount "0" @default.
- W4225647712 crossrefType "journal-article" @default.
- W4225647712 hasAuthorship W4225647712A5011063805 @default.
- W4225647712 hasAuthorship W4225647712A5012326453 @default.
- W4225647712 hasAuthorship W4225647712A5045094923 @default.
- W4225647712 hasAuthorship W4225647712A5078968852 @default.
- W4225647712 hasAuthorship W4225647712A5091574164 @default.
- W4225647712 hasConcept C126322002 @default.
- W4225647712 hasConcept C127413603 @default.
- W4225647712 hasConcept C168563851 @default.
- W4225647712 hasConcept C185592680 @default.
- W4225647712 hasConcept C19038510 @default.
- W4225647712 hasConcept C203092338 @default.
- W4225647712 hasConcept C2776091944 @default.
- W4225647712 hasConcept C2776839432 @default.
- W4225647712 hasConcept C2777171753 @default.
- W4225647712 hasConcept C2780645631 @default.
- W4225647712 hasConcept C3017514745 @default.
- W4225647712 hasConcept C500558357 @default.
- W4225647712 hasConcept C535046627 @default.
- W4225647712 hasConcept C543025807 @default.
- W4225647712 hasConcept C55493867 @default.
- W4225647712 hasConcept C71924100 @default.
- W4225647712 hasConcept C78519656 @default.
- W4225647712 hasConcept C95190672 @default.
- W4225647712 hasConceptScore W4225647712C126322002 @default.
- W4225647712 hasConceptScore W4225647712C127413603 @default.
- W4225647712 hasConceptScore W4225647712C168563851 @default.
- W4225647712 hasConceptScore W4225647712C185592680 @default.
- W4225647712 hasConceptScore W4225647712C19038510 @default.
- W4225647712 hasConceptScore W4225647712C203092338 @default.
- W4225647712 hasConceptScore W4225647712C2776091944 @default.
- W4225647712 hasConceptScore W4225647712C2776839432 @default.
- W4225647712 hasConceptScore W4225647712C2777171753 @default.
- W4225647712 hasConceptScore W4225647712C2780645631 @default.
- W4225647712 hasConceptScore W4225647712C3017514745 @default.
- W4225647712 hasConceptScore W4225647712C500558357 @default.
- W4225647712 hasConceptScore W4225647712C535046627 @default.
- W4225647712 hasConceptScore W4225647712C543025807 @default.
- W4225647712 hasConceptScore W4225647712C55493867 @default.
- W4225647712 hasConceptScore W4225647712C71924100 @default.
- W4225647712 hasConceptScore W4225647712C78519656 @default.
- W4225647712 hasConceptScore W4225647712C95190672 @default.
- W4225647712 hasIssue "1" @default.
- W4225647712 hasLocation W42256477121 @default.
- W4225647712 hasOpenAccess W4225647712 @default.
- W4225647712 hasPrimaryLocation W42256477121 @default.
- W4225647712 hasRelatedWork W1982747617 @default.
- W4225647712 hasRelatedWork W2006544568 @default.
- W4225647712 hasRelatedWork W2073322335 @default.
- W4225647712 hasRelatedWork W2117234943 @default.
- W4225647712 hasRelatedWork W2273958777 @default.
- W4225647712 hasRelatedWork W2290734560 @default.
- W4225647712 hasRelatedWork W3175571475 @default.
- W4225647712 hasRelatedWork W4220951923 @default.
- W4225647712 hasRelatedWork W4323048606 @default.
- W4225647712 hasRelatedWork W2108839487 @default.
- W4225647712 hasVolume "16" @default.
- W4225647712 isParatext "false" @default.
- W4225647712 isRetracted "false" @default.
- W4225647712 workType "article" @default.